NEW YORK (GenomeWeb) – Natera said today that it has entered a research collaboration with Imperial College London and the University of Leicester to retrospectively evaluate the company's Signatera circulating tumor DNA technology for the detection of disease recurrence in breast cancer patients.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.